PARP Inhibitors in the Treatment of Ovarian Cancer
a review of the latest research
DOI:
https://doi.org/10.12775/JEHS.2025.78.57677Keywords
PARP inhibitors, ovarian cancer, ovarian cancer treatmentAbstract
Introduction
Ovarian cancer is a leading cause of cancer mortality globally due to late-stage diagnosis and limited treatment options. PARP inhibitors have shown promise as effective treatments for recurrent and various stages of ovarian cancer.
Aim of the Study
This study reviews the efficacy and application of PARP inhibitors in ovarian cancer treatment over the past 15 years, focusing on literature from the PubMed database post-2009 and considering FDA and EMA guidelines.
Review methods
A literature review was conducted using the PubMed database, focusing on studies published after 2009. The review also incorporated recommendations from the FDA and the European Medicines Agency regarding the use of PARP inhibitors in ovarian cancer treatment.
Results
The findings highlight the substantial impact of PARP inhibitors on ovarian cancer treatment, improving PFS and overall outcomes. Olaparib, niraparib, and rucaparib have become integral to ovarian cancer management, offering effective options for patients with BRCA mutations or homologous recombination deficiencies. These inhibitors have been validated in multiple clinical trials, underscoring their robustness and effectiveness. Combination therapies, such as olaparib with bevacizumab, further enhance therapeutic outcomes, showcasing the potential for synergistic effects.
Summary
PARP inhibitors represent a significant advancement in ovarian cancer treatment, offering improved survival outcomes for patients with specific genetic profiles. Their integration into standard care protocols underscores their importance and efficacy, providing valuable therapeutic options in the fight against ovarian cancer.
References
1. Penny SM. Ovarian Cancer: An Overview. Radiol Technol. 2020;91(6):561-575.
2. Mittica G, Ghisoni E, Giannone G, et al. PARP Inhibitors in Ovarian Cancer. Recent Pat Anticancer Drug Discov. 2018;13(4):392-410. doi:10.2174/1574892813666180305165256
3. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183-203. doi:10.3322/caac.20113.
4. Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol. 2020;8:564601. Published 2020 Sep 9. doi:10.3389/fcell.2020.564601
5. Drew Y. The development of PARP inhibitors in ovarian cancer: from bench to bedside. Br J Cancer. 2015;113 Suppl 1(Suppl 1):S3-S9. doi:10.1038/bjc.2015.394
6. Wu Y, Xu S, Cheng S, Yang J, Wang Y. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. J Ovarian Res. 2023;16(1):6. Published 2023 Jan 7. doi:10.1186/s13048-023-01094-5
7. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134. doi:10.1056/NEJMoa0900212
8. Miller RE, Lewis AJ, Powell ME. PARP inhibitors and immunotherapy in ovarian and endometrial cancers. Br J Radiol. 2021;94(1128):20210002. doi:10.1259/bjr.20210002
9. U.S. Food and Drug Administration. FDA approves olaparib tablets for maintenance treatment in ovarian cancer. FDA. Published December 19, 2014. Accessed January 9, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer
10. U.S. Food and Drug Administration. FDA approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for maintenance treatment in adult patients. FDA. Accessed April 10, 2024. Accessed January 9, 2025. https://www.fda.gov/drugs/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients
11. U.S. Food and Drug Administration. FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancer. FDA. Accessed April 10, 2024. Accessed January 9, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary
12. Smith AJB, Apple A, Hugo A, Haggerty A, Ko EM. Prior authorization for FDA-approved PARP inhibitors in ovarian cancer. Gynecol Oncol Rep. 2024;52:101335. Published 2024 Feb 13. doi:10.1016/j.gore.2024.101335
13. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382-1392. doi:10.1056/NEJMoa1105535
14. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial [published correction appears in Lancet Oncol. 2015 Apr;16(4):e158. doi: 10.1016/S1470-2045(15)70153-1]. Lancet Oncol. 2014;15(8):852-861. doi:10.1016/S1470-2045(14)70228-1
15. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2017 Sep;18(9):e510. doi: 10.1016/S1470-2045(17)30639-3]. Lancet Oncol. 2017;18(9):1274-1284. doi:10.1016/S1470-2045(17)30469-2
16. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505. doi:10.1056/NEJMoa1810858
17. Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2021 Dec;22(12):e539. doi: 10.1016/S1470-2045(21)00672-0]. Lancet Oncol. 2021;22(12):1721-1731. doi:10.1016/S1470-2045(21)00531-3
18. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416-2428. doi:10.1056/NEJMoa1911361
19. Lee A. Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer [published correction appears in Target Oncol. 2022 Jan;17(1):89. doi: 10.1007/s11523-021-00854-x]. Target Oncol. 2021;16(6):839-845. doi:10.1007/s11523-021-00841-2
20. European Medicines Agency. Zejula: EPAR - Product Information. EMA. Accessed January 9, 2025. https://www.ema.europa.eu/en/documents/product-information/zejula-epar-product-information_en.pdf
21. Longoria TC, Tewari KS. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Expert Opin Drug Metab Toxicol. 2018;14(5):543-550. doi:10.1080/17425255.2018.1461838
22. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-2164. doi:10.1056/NEJMoa1611310
23. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28. PMID: 31562799.
24. Lee A. Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer [published correction appears in Target Oncol. 2022 Jan;17(1):89. doi: 10.1007/s11523-021-00854-x]. Target Oncol. 2021;16(6):839-845. doi:10.1007/s11523-021-00841-2
25. European Commission. Community Register of Medicinal Products: Annex. EC. Accessed January 9, 2025. https://ec.europa.eu/health/documents/community-register/2018/20180524140802/anx_140802_pl.pdf
26. Shapiro GI, Kristeleit RS, Burris HA, et al. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2019;8(1):107-118. doi:10.1002/cpdd.575
27. O'Malley DM, Oza AM, Lorusso D, et al. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol Oncol. 2022;167(3):404-413. doi:10.1016/j.ygyno.2022.08.021.
28. Kristeleit RS, Drew Y, Oza AM, et al. Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. Br J Cancer. 2023;128(2):255-265. doi:10.1038/s41416-022-02022-y
29. Guo XX, Wu HL, Shi HY, Su L, Zhang X. The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Manag Res. 2018;10:2553-2562. Published 2018 Aug 10. doi:10.2147/CMAR.S169558
30. Wu L, Zhu J, Yin R, et al. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecol Oncol. 2021;160(1):175-181. doi:10.1016/j.ygyno.2020.10.005
31. Shammo JM, Usha L, Richardson KJ, et al. Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. J Oncol Pract. 2019;15(7):405-407. doi:10.1200/JOP.18.00705
32. Shiraishi C, Hirai T, Kaneda M, et al. Factors for the development of anemia in patients with newly introduced olaparib: A retrospective case-control study. Medicine (Baltimore). 2023;102(30):e34123. doi:10.1097/MD.0000000000034123
33. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372-379. doi:10.1200/JCO.2011.36.9215
34. Pagkali A, Mamais I, Michalinos A, Agouridis AP. Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis. Curr Oncol. 2022;29(1):321-336. Published 2022 Jan 12. doi:10.3390/curroncol29010029
35. Adrianto N, Mangkuliguna G, Tandiono EJ, Sibarani CNR. Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis. Taiwan J Obstet Gynecol. 2024;63(5):601-609. doi:10.1016/j.tjog.2024.05.020
36. Dockery LE, Gunderson CC, Moore KN. Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. Onco Targets Ther. 2017;10:3029-3037. Published 2017 Jun 19. doi:10.2147/OTT.S114714
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Andrzej Paweł Zuzak, Małgorzata Satora, Magdalena Cieślik-Porębska, Krzysztof Kułak, Jagoda Niewiadomska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 65
Number of citations: 0
